Filing Details
- Accession Number:
- 0001209191-23-003866
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-18 19:09:18
- Reporting Period:
- 2023-01-13
- Accepted Time:
- 2023-01-18 19:09:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1679363 | Morphic Holding Inc. | MORF | Pharmaceutical Preparations (2834) | 473878772 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1780270 | William Devaul | C/O Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham MA 02451 | General Counsel And Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-14 | 3,250 | $0.00 | 24,908 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-14 | 1,169 | $30.63 | 23,739 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy Common Stock) | Acquisiton | 2023-01-13 | 62,160 | $0.00 | 62,160 | $31.72 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2023-01-13 | 43,800 | $0.00 | 43,800 | $0.00 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2023-01-14 | 3,250 | $0.00 | 3,250 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 62,160 | 2033-01-12 | No | 4 | A | Direct | |
| 43,800 | No | 4 | A | Direct | ||
| 9,750 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
- The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- The option vests as to 2.0833% of the total shares monthly, beginning February 13, 2023, with 100% of the total shares vested and exercisable on January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
- The RSUs vest as to 25% of the total shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
- The RSUs vest as to 25% of the total shares on each of January 14, 2023, January 14, 2024, January 14, 2025 and January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.
Billionaire Hedge Funds
